Company Overview and News

8
Potentially Oversold Best Of Breed BDC: Initiating Coverage

2018-09-19 seekingalpha
Earlier this year, I initiated active coverage of GAIN (8.2% yield) and its preferred stocks GAINM (6.2% yield) and now its newly issued GAINL (6.3% yield).
AIY AINV CLA GAIN GAINM MCQ KAP PNNT BKCC MCV PFLT OSLE GADDP GAINL GLADO HTGZ KCAP GLAD ABDC MSCA CPTA MCC TCRX ARCC HCAPL FSIC MAIN TCPC AIB TCRD TCRZ PSEC HTGX NMFC HTGY TSLF OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA

1
FSIC / FS Investment Corporation N-14 8C/A

2018-09-18 sec.gov
N-14 8C/A Table of Contents As filed with the Securities and Exchange Commission on September 17, 2018 Registration No. 333-226410
FSIC

7
Approaching Oversold Conditions, Driving 9% Yield With Upcoming Specials

2018-09-13 seekingalpha
I recently purchased additional shares of this higher quality BDC that's trading 6% below book value paying a 9% dividend yield with an upcoming special dividend in Q4.
AIY AINV CLA MCQ KAP PNNT BKCC MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC CPTA MCC TCRX ARCC HCAPL FSIC TCPC AIB TCRD TCRZ PSEC HTGX NMFC TSLF HTGY OCSI ARU OCSL MCX HCAP SUNS HTGC PBB PNTA

6
Main Street Capital's NAV, Dividend, And Valuation Compared To 14 BDC Peers (Post Q2 2018 Earnings) - Part 2

2018-09-13 seekingalpha
Part 2 of this article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK MDLY NEWTL PBB

5
10 Top Gain Financial WallStars Garner 22% To 56% Broker Targets For September 2019

2018-09-11 seekingalpha
WallStars are distinguished by positive broker target price upsides. Five top net-gain financial WallStars, MDLY, BLX, GARS, CPTA, and BBVA averaged 42.29% estimated net gains per one-year targets as of September 7, 2018.
AIY CMFN TCRX AINV GARS CLA FSIC AIC GECC TCPC BVA AIB TCRD TCRZ TSLF AI OFS MDLY CPTA AIW

36
My 94 Stock Portfolio August Value, Income Review, Activity Update, And Sector Additions

2018-09-05 seekingalpha
Global Industry Classification System, GICS, is adjusting sectors in September, for which, I will reveal some of those changes as well as 2 of my own.
AMZN FSIC MS

1
FSIC / FS Investment Corporation null

2018-08-30 sec.gov
FS Investment Corp
FSIC

1
FSIC / FS Investment Corporation null

2018-08-30 sec.gov
FS Investment CORP Cira Centre
FSIC

1
FSIC / FS Investment Corporation null

2018-08-30 sec.gov
FS Investment Corporation FS INVESTMENT CORPORATION 201 ROUSE BOULEVARD PHILADELPHIA, PENNSYLVANIA 19112 (215) 495-1150
FSIC

7
Oil-Exposed BDCs Continue To Rally But Still Yield 9% To 11%

2018-08-29 seekingalpha
Most BDCs with higher exposure to oil-related investments have rebounded over the last two quarters partially due to rising oil prices and LIBOR resulting in higher book values and earnings.
AIY AINV GAIN HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD NMFC TSLF MCX HCAP CLA MCQ GAINM HRZN PNNT MCV GADDP CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA

1
IL&FS Investment: Eyes on Q1 results

2018-08-27 thehindubusinessline
Shares of IL&FS Investment Managers will remain in focus, as the company will declare its first-quarter results of FY18. The company, a subsidiary of Infrastructure Leasing & Financial Services Limited (IL&FS), had reported a loss of ₹7.45 crore for the qurter ended March 2018 on revenues of ₹9.28 crore. For FY2018, net profit declined 83.44 per cent to ₹3.97 crore, against ₹23.97 crore reported during the previous fiscal.
570002 LICHSGFIN FSIC FRLDVR FRL 523574 LHFLY 500253

5
Assessing Oaktree Strategic Income's Results For Fiscal Q3 2018 (Includes Current Recommendation)

2018-08-27 seekingalpha
Due to the recent change in management, readers have asked if I could take a look at OCSI to determine whether operations have improved enough to currently justify an investment.
ACSF AIY AINV GAIN MCQ GAINM OAK MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX BLK NEWTL PBB

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 302635107